We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

Urinary Interleukin-8 May Be the Ultimate Bladder Cancer Biomarker

By LabMedica International staff writers
Posted on 01 Jun 2021
Print article
Image: A platform for multiplexing up to 100 analytes such as proteins in a single well of a microtiter plate (Photo courtesy of Luminex Corporation)
Image: A platform for multiplexing up to 100 analytes such as proteins in a single well of a microtiter plate (Photo courtesy of Luminex Corporation)
A recently published study established that the urinary protein interleukin-8 (IL-8) not only distinguished bladder cancer from controls, it also discriminated high grade from low grade disease, and the successive clinical stages of bladder cancer.

The potential usefulness of this biomarker was determined by investigators at the University of Houston (Texas, USA). These investigators had set out to identify novel urine protein biomarkers of bladder cancer using a Luminex (Austin, TX, USA) based screening platform.

For this study, the investigators analyzed urine samples from 66 subjects, comprised of 31 urology clinic controls and 35 bladder cancer patients, using a Luminex based screening platform. ELISA validation was carried out for the top four prospective urine biomarkers using an independent cohort of 20 urology clinic controls and 60 bladder cancer (BC) subjects.
Results revealed that of the 16 proteins screened by the Luminex platform, 10 showed significant elevation in BC compared to the controls. Eight of these urine proteins were able to differentiate BC from control urine with AUC values exceeding 0.70 with specificity values exceeding 0.9. Upon ELISA validation, urine IL-1alpha, IL-1ra, and IL-8 were able to distinguish control urine from urine drawn from various bladder cancer stages, with IL-8 being the best discriminator. Overall, IL-8 displayed the highest significance in discriminating between controls and BC patients and discriminating highly advanced stages/grades of BC from less advanced stages/grades of BC.

Senior author Dr. Chandra Mohan, professor of biomedical engineering at the University of Houston, said, "Bladder cancer (BC) is the sixth most common cancer diagnosis in the United States and is over four times more common in men than women. Urine biomarkers could potentially provide preliminary confirmation of low-grade BC before invasive procedures are performed and facilitate surveillance of BC."

The Luminex-based study was published in the April 13, 2021, online edition of the journal Oncotarget.

Related Links:
University of Houston

Gold Supplier
ADAMTS13 Activity Assay
HemosIL ACUSTAR ADAMTS13 Activity Assay
SARS-CoV-2 Real-Time RT-PCR Test
GB SARS-CoV-2 Real-Time RT-PCR [E/N/ORF1ab (RdRp)]
Gold Supplier
Nucleic Acid Extraction System
Gold Supplier
SARS-CoV-2 Neutralizing Antibody Test Kit (Fluorescence Immunoassay)
SARS-CoV-2 Neutralizing Antibody Test Kit (Fluorescence Immunoassay)

Print article



view channel

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.